J&J Builds Case for Earlier Tecvayli Use in Multiple Myeloma
Johnson & Johnson reported that Tecvayli (teclistamab) monotherapy cut overall survival risk by 40% in the MajesTEC‑9 trial for patients who had received one to three prior lines of therapy. The same study showed a 71% reduction in progression‑free survival versus pomalidomide‑bortezomib‑dexamethasone or carfilzomib‑dexamethasone. Earlier data from MajesTEC‑3 demonstrated similar benefits when Tecvayli was combined with Darzalex Faspro, prompting J&J to pursue second‑line approval. The company estimates a $5 billion market if the label expands, despite higher fatal infection rates observed in the combination arm.
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
The FDA announced it will postpone its action date for Eli Lilly’s oral obesity drug orforglipron to April 10, 2026, extending the review timeline for the medication. The agency also delayed decisions for three other Commissioner’s National Priority Voucher recipients—Sanofi’s Tzield, Disc Medicine’s...
Compounder Sues Lilly, Novo, Claims Coordinated Crackdown
Arizona‑based Strive Compounding Pharmacy has filed an antitrust lawsuit in Texas against Eli Lilly and Novo Nordisk, accusing the two giants of coordinating with telehealth firms to block compounders from filling GLP‑1 prescriptions. The complaint alleges that the pharma companies restrict payment...
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate
Jazz Pharmaceuticals sold a priority review voucher for $200 million, the highest price in nearly a decade, during its J.P. Morgan Healthcare Conference presentation. The voucher stemmed from the FDA’s August 2025 approval of Modeyso, a rare‑brain‑tumor drug acquired through Chimerix. While...
JPM Day 3: Rare Disease in the Spotlight
Rare‑disease therapeutics dominated day three of J.P. Morgan Healthcare, with five companies outlining 2026 roadmaps. Rocket Pharmaceuticals announced it will resume dosing three Danon disease patients in the first half of 2026 after an FDA hold, while also awaiting a...
Ocugen Touts Phase 2 Data for Eye Disease Gene Therapy
Ocugen announced positive interim Phase 2 data for its geographic atrophy (GA) gene therapy, a leading cause of vision loss in age‑related macular degeneration. The trial, though limited to a small patient cohort, demonstrated measurable improvements in retinal function and...
Cellares Inks Long-Term Lease for IDMO Smart Factory at Leiden Bio Science Park
Cellares has signed a long‑term lease for a 9,741 m² site at Leiden Bio Science Park, designating it as its European headquarters and a new IDMO Smart Factory. The facility will host the company’s automated Cell Shuttle manufacturing platform and Cell...
Novartis Issues a Life Sciences Warning in a 'G-Zero' World
Novartis has sent an open letter to governments in the EU, Canada and Japan warning that fragmented regulation, unpredictable pricing and blunt cost‑control tools are causing Europe to lose life‑science ground to the United States and China. The company, together...
Advancing Human-Machine Interfaces with Memristive Technology
Researchers have unveiled a new memristive architecture that dramatically improves human‑machine interfaces (HMIs). The technology leverages analog resistance states to store and process data directly at the sensor level, cutting latency and power draw. Early prototypes demonstrate real‑time pattern recognition...
J&J Reports Positive Phase 3 Data for Tecvayli in Earlier Blood Cancer Setting
Johnson & Johnson announced that its bispecific antibody Tecvayli (teclistamab) achieved a statistically significant overall survival benefit in a Phase 3 trial evaluating an earlier‑line setting for multiple myeloma. The study reported a hazard ratio of 0.68 for death and extended...
True Colours
The article outlines the gold standard for spectroscopy in pharmaceutical labs, emphasizing that precise colour and turbidity measurements underpin brand integrity, product identification, and patient safety. It profiles six manufacturers—HunterLab, Shimadzu, PerkinElmer, Thermo Fisher Scientific, Agilent, and Mettler Toledo—detailing flagship...
MARS Bioimaging Closes $15M Series A Funding
Medical device startup MARS Bioimaging announced a $15 million Series A round, led by Pacific Channel. The financing was delivered in two tranches—$7.6 million initially and $7.4 million later in 2026. The capital will accelerate deployment of its portable spectral photon‑counting CT scanners across...
Oxford BioMedica Confirms Private Equity Takeover Talks
Oxford BioMedica, a UK contract development and manufacturing organisation specialising in cell and gene therapies, disclosed an unsolicited cash approach from Stockholm‑listed private‑equity group EQT. The news sent the shares up 15% intraday and over a third higher year‑to‑date, reflecting...
A Protein Found in the GI Tract Can Neutralize Many Bacteria
Researchers at MIT have identified intelectin‑2, a lectin produced in the gut, as a broad‑spectrum antimicrobial protein. The molecule binds galactose residues on both mucins and bacterial membranes, reinforcing the mucus barrier and trapping microbes. Trapped bacteria eventually disintegrate, showing...
Novo Nordisk Foundation to Inject $850M+ Into BioInnovation Institute Through 2035
The Novo Nordisk Foundation announced a commitment of 5.5 billion Danish kroner (approximately $857 million) to the BioInnovation Institute, a life‑science and deep‑tech incubator, with funding extending through 2035. The pledge aims to bolster the institute’s capacity to nurture early‑stage biotech and...
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
At the J.P. Morgan Healthcare Conference, venture capitalists highlighted a tightening funding environment for early‑stage biotech firms, driven by a hyper‑concentration of capital among a few investors. VCs now scrutinize founder and CEO attributes, emphasizing regulatory know‑how, market insight, and...
11 Companies Hiring Manufacturing Professionals Now
Big Pharma is accelerating domestic manufacturing hiring as 2026 begins, highlighted by Johnson & Johnson’s plan to add 500 jobs at a new North Carolina plant and AbbVie’s $100 billion ten‑year commitment to U.S. R&D and capital projects. The surge creates...
Spaceflight Study Links Astronaut Biology to Reversible Shifts in Epigenetic Age
A recent Buck Institute study analyzed blood from the four‑person Axiom 2 crew, revealing that a 10‑day spaceflight accelerated epigenetic age by roughly 1.9 years by day 7. Serial sampling showed the acceleration reversed after landing, with older astronauts returning to baseline and...
Chlocarbazomycins: Promising Adenosine A1 Receptor Antagonists
Researchers have identified a new class of natural products called chlocarbazomycins that act as potent antagonists of the adenosine A1 receptor. In preclinical assays, these compounds bind with nanomolar affinity and demonstrate functional activity, lowering heart rate and improving neuronal...
N1-Methylpseudouridine Shapes Translation Dynamics
Researchers have demonstrated that incorporating N1‑methylpseudouridine (m1Ψ) into synthetic mRNA reshapes ribosomal translation dynamics. High‑resolution ribosome profiling shows accelerated elongation rates and altered codon‑specific pausing compared with unmodified uridine. The modification also dampens innate immune sensing, leading to higher protein...
China’s JNBY Group Is Making a Case for Faux Fur, as the Real Thing Falls Out of Fashion
China’s JNBY Group introduced a plant‑based faux‑fur vest for its Croquis menswear line, marking the first large‑scale retail rollout of BioFluff’s Savian material. The collaboration leverages JNBY’s vertically integrated network of over 2,100 stores, allowing the eco‑fur product to reach...
KLHL6 Ubiquitin Ligase Fuels CD8+ T Cell Resistance
Researchers have identified the ubiquitin ligase KLHL6 as a critical driver of CD8+ T‑cell resistance in cancer. KLHL6 promotes degradation of the inhibitory receptor PD‑1, thereby sustaining T‑cell activation within the tumor microenvironment. In mouse models, genetic ablation or pharmacologic...
Psychotropic Medications and Their Interactions with Subcortical Brain Volume in Bipolar Disorder: An ENIGMA Mega-Analysis
The ENIGMA Bipolar Disorder Working Group pooled MRI data from 6,729 participants to examine how psychotropic medications influence subcortical brain volumes in bipolar disorder. Lithium use was associated with larger hippocampal and thalamic volumes, whereas antipsychotics and valproate correlated with...
Associations Between Mosaic Loss and Schizophrenia or Bipolar Disorder of Young Age
Recent genomic studies reveal that somatic mosaic loss, particularly mosaic chromosomal alterations, is significantly associated with early‑onset schizophrenia and bipolar disorder. Analyses of over 12,000 schizophrenia cases identified recurrent somatic copy‑number variants disrupting NRXN1 and ABCB11, while prenatal mutational signatures...
PROTAC Bottleneck Breakthroughs
The latest generation of intracellular PROTACs now offers precise spatial activation, tunable persistence, and expanded ubiquitin‑ligase recruitment, addressing the pharmacokinetic and toxicity hurdles of earlier candidates. Chinese research groups have pioneered formulations that release the degrader only within target cells...
EMA and FDA Collaborate on Framework for AI Use in Drug Development
The U.S. FDA and Europe’s EMA have jointly published ten guiding principles for the use of artificial intelligence across the drug development lifecycle. The framework covers human‑centric design, risk‑based validation, data governance, multidisciplinary expertise, and clear communication of model performance....
Smartphone Measures Vasomotor Function via Fingertip Elasticity
Researchers published a study demonstrating that a standard smartphone can assess vasomotor function by measuring fingertip arteriolar elasticity using green‑light photoplethysmography combined with a volume‑oscillometric method. The technique captures blood‑volume oscillations to infer arterial pressure changes, offering a non‑invasive proxy...
Cryo-EM Maps Autoantibody Hotspots on NMDA Receptors in Autoimmune Encephalitis
A study in Science Advances used cryo‑electron microscopy to map the exact binding sites of anti‑NMDAR autoantibodies on the GluN1 amino‑terminal domain of NMDA receptors. The researchers showed that mouse‑derived antibodies bind the same two hotspots as those isolated from...
Scribe Therapeutics Plans to Test Cholesterol-Lowering Therapy This Summer
The request does not contain the full text of the article titled “Scribe Therapeutics plans to test cholesterol‑lowering therapy this summer,” only a brief placeholder and a sign‑up prompt. Without the substantive content, no executive summary can be generated.
Ultrasound-Activated Nanoparticles in Immune Cells Trigger Targeted Inflammatory Response
Boston College scientists demonstrated that barium titanate piezoelectric nanoparticles internalized by macrophages can be remotely activated with ultrasound, prompting M1‑type inflammatory polarization. By tuning ultrasound intensity they avoided cytotoxicity, while higher power levels selectively killed nanoparticle‑laden cells, hinting at a...
STAT+: Secretive Project Prometheus Takes VC Bob Nelsen Beyond Just Health Care
Venture capitalist Bob Nelsen is spearheading Project Prometheus, an AI‑driven venture that fuses artificial intelligence with physics. The startup is co‑led by Amazon founder Jeff Bezos and former Foresite Capital AI chief Vik Bajaj, with renowned scientist Rick Klausner on board. While...
Manufacturers Benefit as Pharma Customers Invest Back in US
Recent tariff and trade policy shifts that unsettled pharmaceutical firms in 2025 are now creating upside for U.S. manufacturers. Pharma companies are redirecting capital toward domestic production, spurring demand for contract manufacturing and equipment. This investment wave is expected to...
Future Outlook: SARS and COVID-19 Explained
The article offers a forward‑looking comparison of SARS and COVID‑19, detailing their virological differences, transmission dynamics, and the evolution of public‑health responses. It highlights how early containment strategies for SARS informed later COVID‑19 policies, while also exposing gaps in surveillance...
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Sanofi’s CEO Paul Hudson said the firm will acquire Dynavax for $2.2 billion, targeting its adult hepatitis B vaccine Heplisav‑B, as vaccine sentiment wanes under U.S. political rhetoric. Legacy vaccine sales fell 8 % in Q3 2025, prompting a long‑term focus on adult‑focused products...
CRISPR–Cas3 Genome-Editing System Holds Therapeutic Potential
Researchers at the University of Tokyo demonstrated that the CRISPR‑Cas3 system can permanently suppress transthyretin (TTR) production in a mouse model of hereditary amyloidosis. Using lipid‑nanoparticle delivery, they achieved roughly 48% editing of hepatic TTR alleles and an 80% reduction...
Dycem, a contamination‑control specialist, celebrates 60 years since its 1966 founding, tracing roots to a high‑friction polymer discovered in 1960. The company grew from niche non‑slip products to global cleanroom solutions, now present in more than 50 countries and 30,000...
Nonlinear X-Ray Four-Photon Interaction Unveiled
Researchers have reported the first experimental observation of a nonlinear X‑ray four‑photon interaction, a phenomenon previously confined to theoretical models. The breakthrough was achieved using ultra‑intense pulses from a free‑electron laser, enabling simultaneous absorption of four X‑ray photons in a...
Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade
Jazz Pharmaceuticals announced the sale of a priority review voucher to an undisclosed buyer for $200 million, marking the highest price paid for such a voucher in a decade. The voucher, originally granted for developing a treatment for a neglected disease,...
Health Tech Funding Rounds Get Bigger when Andreessen Horowitz and General Catalyst Join
Rock Health’s latest report shows a handful of venture firms dominate health‑tech financing. When Andreessen Horowitz and General Catalyst join a round, the deal size expands dramatically, with average rounds climbing from roughly $30 million to $50 million. Together these two firms...
Program Harnesses the Power of Mentorship for Patient Organization Leaders
The Milken Institute’s FasterCures LeadersLink program, launched in 2020, provides mentorship, peer learning, and capstone projects for emerging leaders of patient advocacy organizations that fund or conduct biomedical research. The cohort‑based model connects mentees with seasoned executives, fostering strategic reflection...
A CRISPR Fingerprint of Pathogenic C. Auris Fungi for Precision Diagnostics
Researchers at Harvard’s Wyss Institute have unveiled dSHERLOCK, a digital CRISPR‑based diagnostic that can detect and quantify Candida auris from swab samples in under 40 minutes while simultaneously identifying antifungal resistance mutations. The platform merges SHERLOCK’s single‑nucleotide precision with single‑molecule...
Natural Fiber Welding Receives Investment From Provest Equity Partners and CTW Venture Partners
Natural Fiber Welding, a Peoria‑based developer of plant‑derived performance materials, secured a strategic investment from Provest Equity Partners and CTW Venture Partners. The undisclosed capital infusion coincides with Suhas Uppalapati joining the board as Chairman. The company will deploy the...
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
Gilead’s new HIV therapy Yeztugo is gaining rapid market traction, achieving 85% payer coverage six months after its June 2025 approval and hitting the $150 million revenue target for the year. CEO Daniel O’Day highlighted voluntary licensing of the drug’s active ingredient,...
2026 Outlook: ‘Slow-Moving Catastrophe’ at FDA
The FDA is entering a ‘slow‑moving catastrophe’ as staffing cuts, politicization, and the erosion of scientific expertise undermine its regulatory capacity. Senior leadership turnover and a hiring freeze have reduced review staff by roughly 15 percent, while political pressure accelerates...
Framework to Optimize Mammalian Cell Culture Media Blending
Researchers from Osaka University and Shimadzu introduced a mathematically precise workflow for chemically defined media (CDM) blending in mammalian cell culture. The three‑step process combines experimental design, cell culture testing, and regression modeling, using PCA to eliminate multicollinearity and D‑optimal...
Drugs From the Deep
Marine organisms have yielded over 40,000 natural compounds, with 13 now FDA‑approved for cancers, viral infections and chronic pain. The primary obstacle to expanding this "blue pharmaceutical" pipeline is supply, as many bioactive molecules occur in minute quantities that are...
Biologics Manufacturers Urged to Develop QC Plans Early
At an upcoming conference, French biotech consultancy INITS will urge biologics manufacturers to establish a chemistry, manufacturing and controls (CMC) management strategy for reference materials early in development. Regulators increasingly demand deep characterization of reference material, especially by Phase III, and...
Regulatory Support Helping Biopharma to Embrace Platform Technologies
Biopharma firms are increasingly adopting platform technologies—standardized manufacturing bases that can be customized with disease‑specific modules—to accelerate product development and cut costs. Experts cite the lipid nanoparticle system used for mRNA vaccines as a prime example, where swapping the mRNA...
Pharmacovigilance Awareness Among Saudi Healthcare Students
A recent cross‑sectional study surveyed 500 Saudi pharmacy and medical students to gauge their understanding of pharmacovigilance (PV). Only 35% demonstrated sufficient knowledge of adverse drug reaction (ADR) reporting, revealing significant curriculum gaps. The researchers recommend integrating mandatory PV modules...
Intermittent Hypobaric Pressure Fights Aging and Osteoporosis
A recent preclinical study demonstrates that intermittent hypobaric pressure (IHP) exposure can mitigate age‑related bone loss and reverse cellular aging markers. Mice subjected to 2‑hour hypobaric cycles three times a week showed a 12% increase in bone mineral density and...